Vinblastine and erythromycin: an unrecognized serious drug interaction

Sheldon W. Tobe; Lillian L. Siu; Sophie A. Jamal; Karl L. Skorecki; Gerard F. Murphy; Ellen Warner

doi:10.1007/bf00686546

Vinblastine and erythromycin: an unrecognized serious drug interaction

Sheldon W. Tobe, Lillian L. Siu, Sophie A. Jamal, Karl L. Skorecki, Gerard F. Murphy, Ellen Warner

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.

Original language	English
Pages (from-to)	188-190
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	35
Issue number	3
DOIs	https://doi.org/10.1007/bf00686546
State	Published - May 1995
Externally published	Yes

Keywords

Erythromycin
Interaction
Vinblastine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/bf00686546

Cite this

@article{d127270b4bd44513a813c9f6d03edb08,

title = "Vinblastine and erythromycin: an unrecognized serious drug interaction",

abstract = "Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.",

keywords = "Erythromycin, Interaction, Vinblastine",

author = "Tobe, {Sheldon W.} and Siu, {Lillian L.} and Jamal, {Sophie A.} and Skorecki, {Karl L.} and Murphy, {Gerard F.} and Ellen Warner",

year = "1995",

month = may,

doi = "10.1007/bf00686546",

language = "אנגלית",

volume = "35",

pages = "188--190",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Vinblastine and erythromycin

T2 - an unrecognized serious drug interaction

AU - Tobe, Sheldon W.

AU - Siu, Lillian L.

AU - Jamal, Sophie A.

AU - Skorecki, Karl L.

AU - Murphy, Gerard F.

AU - Warner, Ellen

PY - 1995/5

Y1 - 1995/5

N2 - Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.

AB - Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.

KW - Erythromycin

KW - Interaction

KW - Vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0028833508&partnerID=8YFLogxK

U2 - 10.1007/bf00686546

DO - 10.1007/bf00686546

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 7805175

AN - SCOPUS:0028833508

SN - 0344-5704

VL - 35

SP - 188

EP - 190

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 3

ER -

Vinblastine and erythromycin: an unrecognized serious drug interaction

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this